

AbbVie Clinical Pharmacology Research Unit
 Information Sheet
 www.abbviephase1.com

Maple Ash

Check In Date: Monday, 11 July, or Monday, 18 July 2022

Study drug and design:

AbbVie is testing an investigational drug, which is approved by the Food and Drug Administration (FDA). The objective of the study is to assess the safety and pharmacokinetics (the amount of drug absorbed in your bloodstream and how your body handles the drug) of a single oral dose under a non-fasting condition.

Minimum Subject Selection Criteria:

YOU may be eligible to take part in this clinical study if you meet the following conditions:

- ◆ Healthy women 45 to 70 years old.
- ◆ Females must be permanently surgically sterile at least 3 months or postmenopausal for at least 1 year.
- ◆ Females of childbearing potential must give consent and abide by contraception requirement.
- ◆ Average weight (BMI 18.0-42.0).
- ◆ Not taking any medications or herbal remedies or supplements.
- ◆ No history of gastrointestinal surgery including removal of gallbladder.
- ◆ No history or latent or active TB infection.
- ◆ No evidence of uncontrolled diabetes.
- ◆ No active severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection.
- ◆ No history of any drug sensitivity or allergy.
- ◆ No history of clinically significant drug or alcohol within 6 months.
- ◆ Non-user of tobacco for at least 6 months.
- ◆ No live vaccine within 4 weeks.
- ◆ No depot drug by injection withing 30 days.
- ◆ No blood or blood product donation within 8 weeks.
- ◆ Not currently enrolled in another interventional clinical study.
- ◆ Has not been previously enrolled in this study.

Screenings at ACPRU in Grayslake

Screening dates: *(To find out if you are suitable to take part in this clinical study)*

- ◆ 22, 23, 24, 27, 28, 29, 30 June 2022, 05, 06, 07, 08, or 11 July 2022. **Additional screening dates may be available.**
- ◆ Screening appointments are between the hours of 0800 and 1145 and take approximately 3 hours.

Stipend:

- ◆ **Screening:** \$75.00. (No compensation if urine drug/alcohol/cotinine screen is positive or if BMI is out of range.)

AbbVie Clinical Pharmacology Research Unit
Information Sheet
www.abbviephase1.com

- ◆ **Study:** Compensation of up to \$1,575.00 may be provided if selected and you complete the study.

Study dates: *(Please note that these dates and times are subject to change)*

Must complete all periods and/or follow up visit(s).

CHECK IN: Monday, 11 July 2022 or Monday, 18 July 2022 at scheduled appointment time.

CHECK OUT: Thursday, 14 July 2022 or Thursday, 21 July 2022 at approximately noon.

PHONE CALL FOLLOW UP: Thursday, 11 August 2022 or Thursday, 18 August 2022.

(A follow up visit may be required for safety. If this occurs, you will be notified and compensated for your visit time and travel)

(Please note that these dates and times are subject to change)

Please call our recruiting office at 1-800-827-2778 to schedule an appointment.